Climb Bio 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Aoife Brennan

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Sep 23

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Feb 01

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

Jun 24

CEO

Aoife Brennan (48 yo)

no data

테뉴어

Dr. Aoife M. Brennan, M.D. M.B., Ch B., BAO, MMSc, MRCPI, is CEO, President and Director at Climb Bio, Inc. (formerly known as Eliem Therapeutics, Inc.) Dr. Brennan serves as Director of Xilio Therapeutics...

리더십 팀

이름	위치	테뉴어	보상	소유권
Aoife Brennan	CEO, President & Director	no data	데이터 없음	데이터 없음
Brett Kaplan	COO & Principal Financial Officer	less than a year	데이터 없음	데이터 없음
Emily Pimblett	Chief Accounting Officer	1.8yrs	데이터 없음	0.011% $ 23.1k
Jo Palmer-Phillips	Chief Development Officer	no data	데이터 없음	데이터 없음
Nishi Rampal	Senior Vice President of Clinical Development	less than a year	데이터 없음	데이터 없음

0.3yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 관리: CLYM 의 관리팀은 경험 (평균 재직 기간 0.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Aoife Brennan	CEO, President & Director	no data	데이터 없음	데이터 없음
Adam Rosenberg	Independent Director	4.1yrs	US$77.16k	0.26% $ 543.2k
Douglas Williams	Chair of Board	no data	데이터 없음	데이터 없음
Simon Tate	Independent Director	5.8yrs	US$22.52k	데이터 없음
Andrew Levin	Director	no data	US$87.91k	0% $ 0
Stephen Thomas	Director	less than a year	데이터 없음	0.15% $ 316.9k
Judith Dunn	Independent Director	3.8yrs	US$69.66k	0% $ 0

3.8yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: CLYM 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

Climb Bio 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Climb Bio, Inc. Announces Board Changes

Eliem Therapeutics, Inc. Announces Executive Changes

Eliem Therapeutics, Inc. Announces Management Changes

Eliem Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Eliem Therapeutics, Inc. and Tenet Medicines, Inc. Announces Management and Organization Changes

Insufficient new directors

Recent updates

Climb Bio, Inc. Announces Board Changes

Climb Bio, Inc. Present Additional Data from the Completed Pmn Trial and Share Clinical Data from A Single Patient with Minimal Change Disease (Mcd) Treated with Budoprutug

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Eliem Therapeutics, Inc. Announces Executive Changes

Eliem Therapeutics, Inc. (NasdaqGM:ELYM) completed the acquisition of Tenet Medicines, Inc. from RA Capital Management, L.P. and others.

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Eliem Therapeutics, Inc. announced that it has received $119.955003 million in funding from RA Capital Management, L.P., Deep Track Capital, LP, Boxer Capital LLC, Samsara BioCapital LLC, Janus Henderson Investors US LLC

Eliem Therapeutics, Inc. Announces Management Changes

Eliem Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Eliem Therapeutics, Inc. announced that it expects to receive $119.955003 million in funding from RA Capital Management, L.P., Deep Track Capital, LP, Boxer Capital LLC, Samsara BioCapital LLC, Janus Henderson Investors US LLC

New major risk - Share price stability

Eliem Therapeutics, Inc. and Tenet Medicines, Inc. Announces Management and Organization Changes

Insufficient new directors

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

New minor risk - Shareholder dilution

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc

Eliem Therapeutics, Inc. Announces the Resignation of Leone Patterson from the Board of Directors

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Price target decreased to US$6.00

Eliem Therapeutics, Inc. Provides Update on Pipeline Progress

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Eliem Therapeutics, Inc. Provides ETX-810 Program Update

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

Eliem Therapeutics, Inc. Announces Last Patient Completed Dosing in Phase 2A Study of ETX-810 in Patients with Lumbosacral Radicular Pain

Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from Russell 2500 Value Index

Eliem Therapeutics Reports Results from its Phase 2A Clinical Trial Investigating ETX-810 for the Treatment of Diabetic Peripheral Neuropathic Pain and Provided an Update on the Status of the ETX-155 Clinical Program in Epilepsy and Depression

Eliem Therapeutics, Inc., Annual General Meeting, May 19, 2022

Eliem Therapeutics, Inc. Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs

High number of new directors

High number of new and inexperienced directors

Eliem Therapeutics, Inc. has completed an IPO in the amount of $80 million.

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령